Skip to main content
. 2020 Jun 17;8(1):e000612. doi: 10.1136/jitc-2020-000612

Figure 4.

Figure 4

PDS0101 increased antigen-specific T cells against HPV16 E7 and reduced tumor volume in the syngeneic mEER tumor model. (A, B) TC-1 tumor bearing female C57BL/6J mice were treated with PBS control, R-DOTAP control, PDS0101 (s.c., 3 weekly doses starting on day 7), bintrafusp alfa (250 µg, i.p., days 7, 9 and 11), and/or NHS-IL12 (50 µg, s.c., day 7). (A) ELIspot assay for IFNγ in splenocytes stimulated with overlapping HPV16 E7 15-mers. Kruskall-Wallis analysis was performed. (B) Comparison between RF9 peptide and overlapping HPV16 E7 15-mer peptides as investigative antigens for IFNγ ELIspot. Mann-Whitney unpaired t-test. (C, D) mEER tumor bearing female C57BL/6J mice (n=11–12 per group) were treated with PDS0101 (s.c., 3 weekly doses starting on day 4) or PBS control (100 µL, s.c). (C) Tumor weights at the end of study. (D) IFNγ ELIspot data from splenocytes stimulated with overlapping HPV16 E7 15-mer peptides in PBS control versus PDS0101 treated mice. *P<0.05, **P<0.01. HPV, human papillomavirus; IFNγ, interferon-γ; i.p. intraperitoneally; s.c., subcutaneously.